Rhythm Pharmaceuticals In... (RYTM)
NASDAQ: RYTM
· Real-Time Price · USD
62.34
-0.56 (-0.89%)
At close: Jun 16, 2025, 3:59 PM
63.20
1.38%
After-hours: Jun 16, 2025, 06:52 PM EDT
-0.89% (1D)
| Bid | 59.75 |
| Market Cap | 3.97B |
| Revenue (ttm) | 136.86M |
| Net Income (ttm) | -170.02M |
| EPS (ttm) | -2.8 |
| PE Ratio (ttm) | -22.26 |
| Forward PE | -45.63 |
| Analyst | Strong Buy |
| Ask | 63.99 |
| Volume | 249,236 |
| Avg. Volume (20D) | 720,965 |
| Open | 62.39 |
| Previous Close | 62.90 |
| Day's Range | 61.24 - 63.28 |
| 52-Week Range | 39.46 - 69.89 |
| Beta | 2.30 |
About RYTM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RYTM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RYTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+5.04%
Rhythm Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
2 months ago
+17.06%
Rhythm Pharmaceuticals shares are trading higher after the company announced that the Phase 3 TRANSCEND trial met its primary endpoint.
2 months ago · seekingalpha.com
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity DisorderRhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmel...
